Predicting Response to Chemotherapy in Breast Cancer
Author Information
Author(s): Burcombe R J, Makris A, Richman P I, Daley F M, Noble S, Pittam M, Wright D, Allen S A, Dove J, Wilson G D
Primary Institution: Mount Vernon Hospital
Hypothesis
Can biological markers predict the response to neoadjuvant anthracycline chemotherapy in operable breast cancer?
Conclusion
The study found that no single biological marker reliably predicted response to chemotherapy, but a significant reduction in Ki-67 after treatment was associated with a higher likelihood of achieving a pathological response.
Supporting Evidence
- Clinical response rates were 78%, radiological response rates were 72%, and pathological response rates were only 38%.
- Patients with a greater than 75% reduction in Ki-67 after chemotherapy had a 77.8% pathological response rate.
- Changes in hormone receptor status were observed in 10 tumors after chemotherapy.
Takeaway
Doctors wanted to see if certain markers in breast cancer could tell if chemotherapy would work. They found that while no single marker was helpful, a big drop in a specific marker called Ki-67 after treatment meant the chemotherapy was likely working.
Methodology
118 patients with operable breast cancer received six cycles of anthracycline-based chemotherapy, and their clinical, radiological, and pathological responses were assessed.
Potential Biases
Potential biases may arise from the selection of patients and the subjective nature of response assessments.
Limitations
The study's findings may not apply to all breast cancer patients, as the majority achieved only partial responses, and the sample size may limit the generalizability of the results.
Participant Demographics
Median age was 48 years, with a range from 25 to 78 years; 59% were premenopausal.
Statistical Information
P-Value
0.004
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website